Literature DB >> 16412488

A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.

Peter J Bredenbeek1, Richard Molenkamp, Willy J M Spaan, Vincent Deubel, Phillippe Marianneau, Maria S Salvato, Dmitry Moshkoff, Juan Zapata, Ilia Tikhonov, Jean Patterson, Ricardo Carrion, Anysha Ticer, Kathleen Brasky, Igor S Lukashevich.   

Abstract

The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16412488      PMCID： PMC1388090          DOI： 10.1016/j.virol.2005.12.001

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  17 in total

1.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  Lassa fever.

Authors:  J B McCormick; S P Fisher-Hoch
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

3.  Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses.

Authors:  M B Oldstone; H Lewicki; D Homann; C Nguyen; S Julien; J E Gairin
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.

Authors:  Igor S Lukashevich; Jean Patterson; Ricardo Carrion; Dmitry Moshkoff; Anysha Ticer; Juan Zapata; Kathleen Brasky; Robert Geiger; Gene B Hubbard; Joseph Bryant; Maria S Salvato
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.

Authors:  P Pushko; J Geisbert; M Parker; P Jahrling; J Smith
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 6.  Hemorrhagic fever viruses as biological weapons: medical and public health management.

Authors:  Luciana Borio; Thomas Inglesby; C J Peters; Alan L Schmaljohn; James M Hughes; Peter B Jahrling; Thomas Ksiazek; Karl M Johnson; Andrea Meyerhoff; Tara O'Toole; Michael S Ascher; John Bartlett; Joel G Breman; Edward M Eitzen; Margaret Hamburg; Jerry Hauer; D A Henderson; Richard T Johnson; Gigi Kwik; Marci Layton; Scott Lillibridge; Gary J Nabel; Michael T Osterholm; Trish M Perl; Philip Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

7.  Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Authors:  J ter Meulen; M Badusche; K Kuhnt; A Doetze; J Satoguina; T Marti; C Loeliger; K Koulemou; L Koivogui; H Schmitz; B Fleischer; A Hoerauf
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.

Authors:  A McAllister; A E Arbetman; S Mandl; C Peña-Rossi; R Andino
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.

Authors:  S Günther; P Emmerich; T Laue; O Kühle; M Asper; A Jung; T Grewing; J ter Meulen; H Schmitz
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

10.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.

Authors:  Giovanna Barba-Spaeth; Randy S Longman; Matthew L Albert; Charles M Rice
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307
View more
  49 in total

1.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

2.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

3.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

4.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

Review 5.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

Review 6.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

8.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

Review 9.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06

10.  Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers.

Authors:  Shuiyun Lan; Lisa McLay Schelde; Jialong Wang; Naveen Kumar; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.